Johnson & Johnson’s Remicade Patent Invalidated
The Patent and Trademark Office sends notice rejection of the company’s Remicade patent.
Johnson & Johnson announced on Feb. 12, 2015 that the company had received a notice of further action from the United States Patent and Trademark Office (PTO) that PTO re-examined and rejected US Patent No. 6,284,471 (‘471) relating to Remicade (infliximab). The company has 60 days to respond to PTO. J&J stated in a press release that the patent, which expires in September 2018, is valid and the company will appeal the rejection.
A revocation of the patent could be good news for Hospira’s biosimilar Inflectra (infliximab), which is approved for use in Central and Eastern Europe and just received approval for use in West Europe. Celltrion, a partner of Hospira, also has a biosimilar version of infliximab, Remsima, which is currently being reviewed for use in the United States by FDA.
Source: Johnson & Johnson
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
